Shire's Daytrana patch for treatment of ADHD symptoms available in retail pharmacies

By Lisa Kerner

Charlotte, N.C., June 29 - Shire plc said its once-daily Daytrana (methylphenidate transdermal system) transdermal medication for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) symptoms is now available in retail pharmacies (10 mg, 15 mg, 20 mg and 30 mg) and trade packages (10 or 30 patches).

ADHD affects about 4.4 million children in the United States.

Developed by Noven Pharmaceuticals, Inc., Daytrana provides continuous release of medication throughout the day and stays on the child during the normal daily activities such as swimming, exercising or bathing.

"Since the effect of the medication in Daytrana starts to decrease upon patch removal, the ADHD patch allows parents, at the direction of the physician, to vary the duration of effect of the medication up to the recommended nine-hour wear time," said Oscar Bukstein of the Pittsburgh School of Medicine in a news release.

Shire is a specialty pharmaceutical company located in Philadelphia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.